A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors.
暂无分享,去创建一个
A. Tolcher | A. Mita | S. Antonia | J. Mahany | N. Reddy | L. Lewis | D. Buell | A. Keating | E. Till